March 24, 2016Current Medical Research and Opinion
Doses of apixaban and rivaroxaban prescribed in real-world United States cardiology practices compared to registration trials
Why the study?
Does real-world prescribing of reduced dose apixaban and rivaroxaban by U.S. cardiologists differ from utilization in their registration trials?
Population
Prescriptions for apixaban or rivaroxaban written by U.S. cardiologists in the I.M.S. LifeLink dataset
Comparison
Real-world prescribing of reduced dose apixaban… vs Utilization of reduced doses in corresponding…
Design
Cross-sectional
Authors
Discussion
Loading...
Member takes
Implication
Higher real-world reduced-dose apixaban use than trials may signal dosing mismatch; leaves open effects on outcomes and need for prospective study.
Structured PICO
Does real-world prescribing of reduced dose apixaban and rivaroxaban by U.S. cardiologists differ from utilization in their registration trials?
P
Population
Prescriptions for apixaban or rivaroxaban written by U.S. cardiologists in the I.M.S. LifeLink dataset (19 September 2014-11 September 2015)
I
Intervention
Real-world prescribing of reduced dose apixaban (2.5 mg) or rivaroxaban (15 mg)
C
Comparator
Utilization of reduced doses in corresponding nonvalvular atrial fibrillation registration randomized trials
O
Outcome
Proportion of prescriptions for a reduced dose
Real-world U.S. cardiologists prescribe reduced-dose apixaban significantly more often than was utilized in its registration trial, highlighting a potential discrepancy in appropriate dosing.
Cite This Study
Nguyen et al. (2016) studied this question.